Friedrich-Baur-Institut
Welcome,         Profile    Billing    Logout  
 6 Trials 
4 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Klopstock, Thomas
NCT04604548: The KHENEREXT Study

Completed
2
11
Europe
Oral administration of 100 mg KH176 twice daily
Khondrion BV, Julius Clinical, ProPharma Group, Certara
Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A
06/23
06/23
STRIDE, NCT04535609 / 2020-002855-40: An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients

Completed
2
213
Europe, Canada, US, RoW
Mavodelpar, REN001, Placebo
Reneo Pharma Ltd
Primary Mitochondrial Myopathy
09/23
10/23
PMD-OPTION, NCT05972954 / 2022-003307-16: OMT-28 in Patients With Primary Mitochondrial Disease (PMD)

Active, not recruiting
2
32
Europe
OMT-28
Omeicos Therapeutics GmbH, OMEICOS Therapeutics GmbH
Primary Mitochondrial Disease
03/25
06/25
NCT06623890: A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors

Recruiting
N/A
300
Europe, US, RoW
Omaveloxolone, SKYCLARYS, BIIB141
Biogen
Friedreich Ataxia
10/29
10/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Klopstock, Thomas
NCT04604548: The KHENEREXT Study

Completed
2
11
Europe
Oral administration of 100 mg KH176 twice daily
Khondrion BV, Julius Clinical, ProPharma Group, Certara
Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A
06/23
06/23
STRIDE, NCT04535609 / 2020-002855-40: An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients

Completed
2
213
Europe, Canada, US, RoW
Mavodelpar, REN001, Placebo
Reneo Pharma Ltd
Primary Mitochondrial Myopathy
09/23
10/23
PMD-OPTION, NCT05972954 / 2022-003307-16: OMT-28 in Patients With Primary Mitochondrial Disease (PMD)

Active, not recruiting
2
32
Europe
OMT-28
Omeicos Therapeutics GmbH, OMEICOS Therapeutics GmbH
Primary Mitochondrial Disease
03/25
06/25
NCT06623890: A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors

Recruiting
N/A
300
Europe, US, RoW
Omaveloxolone, SKYCLARYS, BIIB141
Biogen
Friedreich Ataxia
10/29
10/29

Download Options